HRTX vs QIPT
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
HRTX presents a high-risk profile characterized by a stable but mediocre Piotroski F-Score of 4/9 and a complete lack of positive technical momentum (0/100). While the company maintains strong gross margins (72.64%) and a healthy current ratio (2.48), these are overshadowed by an extreme Debt/Equity ratio of 9.81 and a catastrophic 5-year price decline of 94.8%. There is a severe disconnect between the 'Strong Buy' analyst consensus with a $4.33 target and the actual market performance and fundamental leverage.
QIPT exhibits significant financial fragility, highlighted by a weak Piotroski F-Score of 3/9 and a concerning Quick Ratio of 0.60. While revenue growth is robust at 32% YoY, the company struggles with consistent profitability and a track record of missing earnings estimates. The current valuation is disconnected from fundamentals, evidenced by an extreme Forward P/E of 182.50. Despite a recent price rally to 52-week highs, the underlying deterministic health metrics suggest a high risk of regression.
Compare Another Pair
Related Comparisons
HRTX vs QIPT: Head-to-Head Comparison
This page compares Heron Therapeutics, Inc. (HRTX) and Quipt Home Medical Corp (QIPT) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.